Verona Investors Gasp As Lead Asset Misses Main Endpoint In COPD Trial
Verona’s shares sank after a brief three-day Phase II trial using lead asset RPL554 in patients already maximally bronchodilated on both a LAMA and LABA missed the primary endpoint.
You may also be interested in...
Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie
Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.